Follow the people · Insider
Kelly Brady
Kelly Brady files insider transactions with the SEC as an officer of Seres Therapeutics (MCRB). We hold 2 disclosed purchases and sales filed since 11 March 2026, 1 of them in the last 90 days.
- Files forMCRB
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure18 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 4 March 2026 — 17 August 2026Officer · Seres Therapeutics (MCRB)11 Form 4 lines · source: SEC Form 4
Everything they disclosed
11 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 181 shares of Seres TherapeuticsSEC Form 418 August 2026Common Stock · traded 15 August 2026 · filed 18 August 2026
- ▼ sold on the open market 64 shares of Seres TherapeuticsSEC Form 418 August 2026Common Stock · traded 17 August 2026 · filed 18 August 2026
- exercised options over 90 shares of Seres Therapeutics (a derivative holding)SEC Form 418 August 2026Restricted Stock Units · traded 15 August 2026 · filed 18 August 2026
- exercised options over 91 shares of Seres Therapeutics (a derivative holding)SEC Form 418 August 2026Restricted Stock Units · traded 15 August 2026 · filed 18 August 2026
- was granted 18,750 shares of Seres Therapeutics (a derivative holding)SEC Form 410 July 2026Stock Option (right to buy) · traded 8 July 2026 · filed 10 July 2026
- exercised options over 180 shares of Seres TherapeuticsSEC Form 419 May 2026Common Stock · traded 15 May 2026 · filed 19 May 2026
- ▼ sold on the open market 59 shares of Seres TherapeuticsSEC Form 419 May 2026Common Stock · traded 18 May 2026 · filed 19 May 2026
- exercised options over 89 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2026Restricted Stock Units · traded 15 May 2026 · filed 19 May 2026
- exercised options over 91 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2026Restricted Stock Units · traded 15 May 2026 · filed 19 May 2026
- was granted 56,250 shares of Seres Therapeutics (a derivative holding)SEC Form 411 March 2026Stock Option (right to buy) · traded 4 March 2026 · filed 11 March 2026
- was granted 56,250 shares of Seres Therapeutics (a derivative holding)SEC Form 411 March 2026Stock Option (right to buy) · traded 4 March 2026 · filed 11 March 2026
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.